Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g…
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…
Asthma is a common chronic airway disease that affects children and adults. Environmental factors and a rapidly changing lifestyle have increased the incidence and prevalence of asthma in China…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is…
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…
The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…
China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…